The WIN (Worldwide Innovative Networking in personalized cancer medicine) Consortium General Assembly unanimously voted adhesion of the EORTC to the WIN Consortium.
WIN Consortium is a non-profit global collaboration of leading academic, industry, healthplan and advocacy organizations. It focusses its efforts on running global research projects to identify biomarkers for targeted therapies as well as clinical trials to investigate targeted cancer treatments.
Dr. Vladimir Lazar, Chief Operating Officer of the WIN Consortium, warmly welcomed the EORTC to the consortium. The EORTC joins DKFZ (Deutsches Krebsforschungszentrum) and AstraZeneca and new WIN Consortium members.
Dr. Francoise Meunier, EORTC Director General, says, “It is certainly a great step forward for the EORTC to join WIN. We are very enthusiastic about such a productive collaboration within the consortium and to developing exciting joint projects for the benefit of patients with cancer. We find that the mission of WIN to accelerate the pace and reduce the cost of translating the most promising innovations in personalized cancer medicine into the standard of care worldwide, aligns well with that of the EORTC, to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life.”
The upcoming WIN 2014 Symposium on 23 – 24 June 2014 in Paris will focus on breakthrough biomarker investigations and combination therapies for cancer.
John Bean, PhD
EORTC, Medical Science Writer